178 related articles for article (PubMed ID: 35879680)
1. The Endothelial Activation and Stress Index (EASIX) score is an independent prognostic factor in patients with diffuse large B-cell lymphoma.
Park S; Go SI; Lee GW
BMC Cancer; 2022 Jul; 22(1):816. PubMed ID: 35879680
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
[TBL] [Abstract][Full Text] [Related]
4. Endothelial activation and stress index as a prognostic factor of diffuse large B-cell lymphoma: the report from the nationwide multi-center Thai Lymphoma Study Group.
Thanhakun R; Wudhikarn K; Bunworasate U; Rattanathammethee T; Norasetthada L; Kanya P; Chaloemwong J; Wongkhantee S; Phiphitaporn P; Chansung K; Jit-Ueakul D; Laoruangroj C; Prayongratana K; Wong P; Julamanee J; Lekhakula A; Chuncharunee S; Niparuck P; Kanitsap N; Makruasi N; Suwanban T; Praditsuktavorn P; Khuhapinant A; Intragumtornchai T;
Ann Hematol; 2023 Dec; 102(12):3533-3541. PubMed ID: 37718327
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y
Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206
[TBL] [Abstract][Full Text] [Related]
6. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
7. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
8. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma].
Huang HW; Jiang YB; Fu TW; Xu T; Chen XC; Jin ZM; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):602-6. PubMed ID: 27535862
[TBL] [Abstract][Full Text] [Related]
10. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era.
Nakayama S; Matsuda M; Adachi T; Sueda S; Ohashi Y; Awaji S; Hashimoto S; Matsumura I
Platelets; 2019; 30(5):637-645. PubMed ID: 30047815
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
Yamamoto M; Watanabe K; Fukuda T; Miura O
Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
[TBL] [Abstract][Full Text] [Related]
12. Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma.
Kanemasa Y; Shimoyama T; Sasaki Y; Hishima T; Omuro Y
Ann Hematol; 2018 Jun; 97(6):999-1007. PubMed ID: 29427185
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.
Ho CL; Lu CS; Chen JH; Chen YG; Huang TC; Wu YY
Medicine (Baltimore); 2015 Jun; 94(24):e993. PubMed ID: 26091479
[TBL] [Abstract][Full Text] [Related]
14. Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Zhou Q; Wei Y; Huang F; Wei X; Wei Q; Hao X; Zhang Y; Feng R
Int J Hematol; 2016 Oct; 104(4):485-90. PubMed ID: 27393279
[TBL] [Abstract][Full Text] [Related]
15. Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma.
Song GY; Jung SH; Kim K; Kim SJ; Yoon SE; Lee HS; Kim M; Ahn SY; Ahn JS; Yang DH; Kim HJ; Lee JJ
BMC Cancer; 2020 Aug; 20(1):803. PubMed ID: 32831058
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
17. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy.
Song MK; Chung JS; Seol YM; Kim SG; Shin HJ; Choi YJ; Cho GJ; Shin DH
Ann Oncol; 2010 Jan; 21(1):140-4. PubMed ID: 19887468
[TBL] [Abstract][Full Text] [Related]
18. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP.
Wang J; Zhou M; Xu JY; Yang YG; Zhang QG; Zhou RF; Chen B; Ouyang J
Medicine (Baltimore); 2016 Sep; 95(38):e4893. PubMed ID: 27661033
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]